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Stage   aEst. % General treatment recommendations
5-year overall survival b
clinical stage path. stage
IA 14% Surgical resection 50% 73%
IB 10% Surgical resection, can consider adjuvant chemotherapy in selected cases (e.g. tumor size > 4cm) 43% 58%
IIA 6% Surgical resection followed by adjuvant chemotherapy 36% 46%
IIB 5% Surgical resection followed by adjuvant chemotherapy 25% 36%
IIIA 16% Multimodality treatment: chemotherapy, radiation, +/- surgery 19% 24%
IIIB 8% Multimodality treatment: chemotherapy and radiation 7% 9%
IV 41% Chemotherapy, consider targeted therapies according to driver mutations 2% N/A
Mutations in TP53 and STK11/LKB1 are common occurrences, not included
in pie chart due to high overlap with other mutations
aEstimated from SEER validation set of proposed 7th edition IASLC staging.
bOverall survival is higher by pathologic stage because clinical stage, which is estimated by clinical characteristics based on CT scan, PET, etc., can underestimate the true stage.
Mutations in TP53 are a common occurrence, not included in
pie chart due to high overlap with other mutations
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Proteins in bold are current
targets of drug development.
*Denotes proteins commonly 
mutated in lung cancer.
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The treatment and diagnosis of non-small cell lung cancer (NSCLC) has been revolutionized by the development of targeted agents for cancers harboring specific genetic muta-
tions. The top table in the adjacent figure summarizes the current clinical landscape of NSCLC. Several somatic “driver” mutations have been described in lung cancer, with 
the spectra and frequencies of mutations differing between adenocarcinoma and squamous cell carcinoma. The pie charts display the current understanding of the mutation 
frequencies in these subsets of NSCLC.
Routine genetic testing for somatic mutations from lung cancer biopsies is becoming the standard for providing optimal patient care. Identification of specific mutations such 
as in EGFR and ALK directs use of FDA-approved targeted therapies that are likely to provide clinical benefit. The identification of other genetic mutations can direct patients 
and physicians toward appropriate clinical trials with new targeted agents. Many of the therapies currently under development target activated receptor tyrosine kinases (RTKs) 
or associated downstream signaling pathways, particularly the RAS-RAF-MAPK and PI3K-AKT pathways. The accompanying pathway diagram highlights the proteins that are 
currently being targeted in NSCLC, and the accompanying table lists the targeted therapies that are FDA approved or currently under active development for treating NSCLC. 
There are numerous clinical trials currently underway assessing how to best target specific pathways (alone or in combination) in cancers harboring specific mutations.
EGFR
Activating EGFR mutations are located in the tyrosine kinase domain and result in constitutive EGFR signaling. Mutant EGFR activates the PI3K-AKT and RAS-MEK-ERK path-
ways that are central to the growth, survival, and migration of cancer cells. The most common activating mutations are in-frame deletions in exon 19 and a missense mutation at 
codon 858 that leads to an arginine to leucine substitution (L858R). Lung cancers with EGFR mutations are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). Currently, 
genotype screening for mutations in EGFR is often used to select patients with stage IV NSCLC who will receive EGFR TKIs in the first-line setting. Current research is focused 
on improving the duration of response and finding effective ways to target the resistance mechanisms that develop at the time of progression. The most common resistance 
mechanism is the EGFR T790M mutation found in ~50% of resistant tumors, but several others, such as MET amplification, PIK3CA mutations, and transformation to SCLC, 
have also been described.
ALK
An inversion in chromosome 2 results in a fusion gene combining EML4 and ALK, which encodes a fusion protein with constitutive activation of ALK resulting from ligand-inde-
pendent dimerization. ALK signaling leads to cellular proliferation and growth through activation of RAS-MEK-ERK, JAK3-STAT3, and PI3K-AKT pathways. ALK translocations in 
NSCLC are associated with adenocarcinoma histology and signet ring cell morphology and with younger patient age and nonsmoking history. A large phase I study of crizotinib, 
which inhibits ALK and several other kinases, demonstrated an overall response rate of 57% and disease control rate of 90% in patients whose cancers harbor ALK transloca-
tions, leading to FDA approval in this indication. More potent ALK inhibitors and strategies targeting acquired resistance are currently being investigated.
ROS1
Chromosomal rearrangements involving the ROS1 gene are identified in ~1.5% of lung adenocarcinomas. Similar to ALK-positive cancers, patients with ROS1-positive cancers 
tend to be younger, never-smokers, and with adenocarcinoma. Responses to crizotinib in patients whose cancers harbor ROS1 translocations have been identified.
KRAS
KRAS is one of the most frequently mutated genes in lung cancer, occurring in ~25% of adenocarcinomas. KRAS mutations in lung cancer localize primarily to codons 12 and 13. 
KRAS mutations in lung cancer appear to be mutually exclusive with EGFR mutations and with ALK translocations and are more often associated with patients with a smoking 
history. KRAS mutations are associated with resistance to EGFR TKI therapy. Although no drugs are currently in development that directly target mutant KRAS, strategies using 
newer targeted therapies in combination with chemotherapy or other targeted therapies, for example, combined PI3K and MEK inhibition, are under clinical development.
PI3K
Mutations in PIK3CA are clustered in two hotspot regions, exons 9 and 20, encoding the helical and kinase domains of the protein, respectively. These mutations result in 
heightened lipid kinase activity and constitutive PI3K-AKT signaling. There are multiple PI3K inhibitors in development, with specificity ranging from dual PI3K/MTOR inhibition 
to pan-PI3K to isoform-selective PI3K inhibitors. Preclinical data suggest that cancers harboring activating mutations in PIK3CA are among the most sensitive to single-agent 
PI3K pathway inhibitors, and clinical trials are underway in lung cancer examining this hypothesis.
PTEN
The tumor suppressor gene PTEN encodes a lipid phosphatase that negatively regulates the PI3K-AKT pathway, and loss of PTEN leads to constitutive PI3K-AKT signaling. 
PTEN is inactivated in many cancers through various mechanisms. PTEN loss is more common in squamous cell cancers than adenocarcinomas. Clinical trials are assessing 
the efficacy of PI3K inhibitors in cancers with PTEN loss.
FGFR1
FGFR1 is a potential target in squamous cell lung cancer. FGFR1 is a member of the FGFR family of RTKs. FGFR1 activation leads to downstream signaling via PI3K-AKT and 
RAS-MEK-MAPK. FGFR1 amplification is observed in ~20% of squamous cell cancer. In laboratory studies, inhibition of FGFR1 both in cancer cell lines and in mouse models 
harboring FGFR1 amplification leads to growth inhibition and apoptosis. Multiple FGFR inhibitors are in clinical development, many of which inhibit multiple tyrosine kinases in 
addition to FGFR1.
PDGFRA
PDGFRA amplification is observed in lung squamous cell cancers. Inhibition of PDGFRA via shRNA knockdown or small molecule inhibition impairs cell survival and anchorage-
independent growth, suggesting that PDGFRA may be a driver oncogene in a subset of cancers with PDGFRA amplification. Multiple PDGFR inhibitors are in clinical develop-
ment. Similar to the FGFR1 inhibitors, many of these agents inhibit multiple kinases.
DDR2
DDR2 is a RTK that binds collagen and promotes cell migration, proliferation, and survival. DDR2 mutations were identified in squamous cell lung cancers and cell lines. In cell 
lines with DDR2 mutations, suppression of DDR2 activity led to inhibition of proliferation. Ectopic expression of mutant DDR2 led to cellular transformation, although different 
mutations had varying levels of transformative capability. These results suggest that DDR2 mutations may be oncogenic and that cancers with these mutations may be sensitive 
to DDR2 kinase inhibitors.
BRAF
BRAF mutations are found in 1%–3% of NSCLC. While V600E is the most common mutation, multiple other types of BRAF mutations have been reported in lung cancer, including 
G469A and D594G. While specific drugs such as vemurafenib are highly active in melanomas harboring BRAF V600E mutations, the activity of these drugs in BRAF mutant lung 
cancer remains to be assessed. Multiple trials assessing the activity of BRAF and MEK inhibitors are underway for cancers harboring BRAF mutations.
Targeted therapies are being developed in the metastatic, or stage IV, lung cancer setting. In metastatic lung cancer, surgery and radiation therapy are usually not indicated, and 
treatment centers on systemic therapy. Because these novel drugs show promise in the metastatic setting when used in cancers with specific genetic mutations, future direc-
tions may include implementing these treatment strategies in the adjuvant setting to improve cure rates.
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